Insight
partnering360® also provides insightful content that gives executives a partnering edge. Tune in here to see high-profile panels, workshops, and interviews with leading dealmakers.
BIO-Europe Spring 2012
The assessment and management of assets: How to position the asset to attract a deal
Mar 20, 2012
There is still a great deal to learn about how to better position an asset to attract investors or deal partners, with an understanding of both short and long term goals.
view full session here 
|
Regional focus: Leveraging commercial rights for emerging markets
Mar 19, 2012
Life science companies are shifting focus to take advantage of specialty indications and regional markets, such as China, the Middle East, Russia and South America
|
view full session here
|
Biotech business models for faster returns
Mar 19, 2012
Nimble entrepreneurs are developing funds and corporate structures that may once again make private biotech an attractive investment, focusing on the drug, not the company.
|
view full session here
|
Close up and personal: Recent deals examined from both sides
Mar 19, 2012
With special emphasis on Dutch biotech deals, executives discuss what the dealmaking hurdles were, what they learned from the process, and how the alliance has been managed
|
view full session here
|
Examining major deals of the past year
Mar 19, 2012
Panelists examine significant deals of 2011, including what these deals reveal about pharma’s priorities, strategy and the options available to drug development companies.
|
view full session here
|
Biotech Showcase 2012
Case study of the AstraZeneca/Rigel partnership
Jan 10, 2012
Executives from both companies discuss the partnership between AstraZeneca and Rigel that was recognized as the deal of the year by SCRIP in 2010.
|
view full session here
|
Shifting sands: What will drive the next phase of value for the pharma and biotech industries?
Jan 10, 2012
The interests of large pharma have shifted from filling late stage pipeline gaps to deals in early stage assets. How will this affect the partnering strategies of biotechs?
|
view executive recap here
|
view full session here
|
BIO-Europe 2011
Have the tables turned? Rethinking big pharma and biotech's approach to niche markets
Oct 31, 2011
There is a rising interest in assets in some therapeutic areas: those where access is assured, patients are more easily identified, and the commercial call-point is narrow.
|
view executive recap here
|
view full session here
|
Changing focus: Creating deal and business models with faster returns in mind
Oct 31, 2011
A few nimble entrepreneurs are developing innovative approaches to rethinking drug development that may once again make private biotech companies attractive investments.
|
view executive recap here
|
view full session here
|
A look at recently renegotiated deals
Oct 31, 2011
Biotech/pharma licensing deals face many challenges, including the possibility of deal termination due to lack of efficacy, safety or due diligence concerns.
|
view full session here
|
Recognizing and avoiding mistakes that can cost you the deal
Oct 31, 2011
Valuable lessons are learned when experienced BD executives draw from their dealmaking experience and dive into some of the common and not so common pitfalls in partnering.
|
view executive recap here
|
view full session here
|
The Takeda/Nycomed 2011 deal
Oct 31, 2011
Nycomed fielded several offers before Takeda landed the prize that resulted in one of 2011's most significant deals.
|
view full session here
|
Non-traditional partnerships in the new healthcare ecosystem
Oct 31, 2011
Future health outcomes may depend on non-traditional partnerships and alliances that focus on the individual patient in a more holistic approach.
|
view full session here
|
